27774208927_ec889a371c_b

More young coronavirus patients being hospitalised in Europe and US compared to China

pharmafile | March 23, 2020 | News story | Sales and Marketing COVID-19, Wuhan Coronavirus, china coronavirus, coronavirus 

Dr Anthony Fauci, the Director of the National Institute of Allergy and Infectious Disease in the US, said that people between the ages of 20 and 44 have been more seriously impacted by the coronavirus in Europe and the US compared to China.

On Sunday, Fauci told the press that: “We have to look at the young people who are getting seriously ill from the European cohort, and make sure it isn’t just driven by the fact that they have underlying conditions, because we know that, with underlying conditions, all bets are off — no matter how young you are.

“If they don’t have underlying conditions, that will be something we have to really examine as to why we’re seeing it here, but we didn’t see it in China.”

New York has seen some of the highest rates of coronavirus cases, and the State’s Governor Andrew Cuomo said that 54% of these patients are between 18 and 49.

America has been one of the outliers in its approach to the pandemic, with only one in four Americans being ordered to stay at home. One of the most populace states, California, ordered all 40 million of its citizens to stay at home unless they do essential jobs.

Global cases of COVID-19 have passed 300,000 and over 13,000 people have died from the virus. In the US there have been over 27,000 cases.

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content